Cargando…

VSIG4 mediates transcriptional inhibition of Nlrp3 and Il-1β in macrophages

Hyperactivation of the NLRP3 inflammasome contributes to the pathogenesis of multiple diseases, but the mechanisms underlying transcriptional regulation of Nlrp3 remain elusive. We demonstrate here that macrophages lacking V-set and immunoglobulin domain–containing 4 (Vsig4) exhibit significant incr...

Descripción completa

Detalles Bibliográficos
Autores principales: Huang, Xiaoyong, Feng, Zeqing, Jiang, Yuanzhong, Li, Jialin, Xiang, Qun, Guo, Sheng, Yang, Chengying, Fei, Lei, Guo, Guoning, Zheng, Lixin, Wu, Yuzhang, Chen, Yongwen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for the Advancement of Science 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6326752/
https://www.ncbi.nlm.nih.gov/pubmed/30662948
http://dx.doi.org/10.1126/sciadv.aau7426
Descripción
Sumario:Hyperactivation of the NLRP3 inflammasome contributes to the pathogenesis of multiple diseases, but the mechanisms underlying transcriptional regulation of Nlrp3 remain elusive. We demonstrate here that macrophages lacking V-set and immunoglobulin domain–containing 4 (Vsig4) exhibit significant increases in Nlrp3 and Il-1β transcription, caspase-1 activation, pyroptosis, and interleukin-1β (IL-1β) secretion in response to NLRP3 inflammasome stimuli. VSIG4 interacts with MS4A6D in the formation of a surface signaling complex. VSIG4 occupancy triggers Ser(232) and Ser(235) phosphorylation in MS4A6D, leading to activation of JAK2-STAT3-A20 cascades that further results in nuclear factor κB suppression and Nlrp3 and Il-1β repression. Exaggerated NLRP3 and IL-1β expression in Vsig4(−/−) mice is accountable for deleterious disease severity in experimental autoimmune encephalomyelitis (EAE) and resistance to dextran sulfate sodium (DSS)–induced colitis. The agonistic VSIG4 antibodies (VG11), acting through NLRP3 and IL-1β suppression, show significant therapeutic efficacy in mouse EAE. These findings highlight VSIG4 as a prospective target for treating NLRP3-associated inflammatory disorders.